tiprankstipranks
Advertisement
Advertisement
Purple Biotech announces collaboration with Converge Bio
PremiumThe FlyPurple Biotech announces collaboration with Converge Bio
2M ago
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
Premium
TipRanks Newswire
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
2M ago
Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
Premium
Company Announcements
Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
2M ago
Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform
PremiumCompany AnnouncementsPurple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform
2M ago
Purple Biotech CEO Gil Efron to step down in August
Premium
The Fly
Purple Biotech CEO Gil Efron to step down in August
2M ago
Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year
Premium
The Fly
Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year
2M ago
PPBT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsPPBT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Purple Biotech Unveils January 2026 Corporate Update, Mapping 2026 Catalysts for CAPTN-3 and Oncology Pipeline
Premium
Company Announcements
Purple Biotech Unveils January 2026 Corporate Update, Mapping 2026 Catalysts for CAPTN-3 and Oncology Pipeline
4M ago
Purple Biotech Reports Key Toxicology Milestone for CAPTN-3 Antibody IM1240
Premium
Company Announcements
Purple Biotech Reports Key Toxicology Milestone for CAPTN-3 Antibody IM1240
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100